4 completed, 1 not yet recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow GLA-SE adjuvant: new trials by email Literature Review of GLA-SE adjuvant trials Research Report on GLA-SE adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant - HIV Prevention | Phase 2 | Not yet recruiting | Worcester HIV Vaccine | 126 | 2026-09-01 | 2026-06-30 |
| Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant - HIV Infections | Phase 1 | Completed | Worcester HIV Vaccine | 42 | 2021-07-08 | 2024-04-09 |
| Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants CH505TF gp120, GLA-SE adjuvant, Placebo - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 38 | 2020-11-10 | 2026-01-29 |
| Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2018-03-16 | 2022-04-25 |
| Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults CH505TF, CH505w53, CH505w78 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 117 | 2017-08-22 | 2026-05-04 |
HIV Infections (4)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Worcester HIV Vaccine (2) · HIV Vaccine Trials Network (1)
United States (4) · South Africa (2)
Avy Violari (1) · Conasagrie Nair, PhD, MD (1) · Georgia Tomaras (1) · Ian Frank (1) · James Kobie (1) · Magda Sobieszczyk (1) · Stephen Walsh, PhD, MD (1) · Turner Overton (1)
PMID 34099325, PMID 38692824, PMID 39484284, PMID 40178906, PMID 40190112, PMID 41212034
UM1AI068614 (1)